1. Introduction {#sec1-cancers-10-00214}
===============

Polycythemia vera (PV) is a clonal hematopoietic stem cell disorder classified as a *BCR/ABL1*-negative myeloproliferative disease (MPD) with a variable risk of transformation into myelodysplasia (MDS) or acute myeloid leukemia (AML) \[[@B1-cancers-10-00214],[@B2-cancers-10-00214]\]. It is characterized by a clonal increase in red blood cells, granulocytes and platelets, with erythrocytosis being the hallmark of the disease. The major contributor to the death of patients with PV appears to be AML/MDS, but there is no generally applicable way to predict which patient is likely to acquire this fatal complication.

Cytogenetic abnormalities have been found in approximately 13--35% of patients with PV at the time of diagnosis \[[@B3-cancers-10-00214],[@B4-cancers-10-00214],[@B5-cancers-10-00214],[@B6-cancers-10-00214],[@B7-cancers-10-00214],[@B8-cancers-10-00214],[@B9-cancers-10-00214],[@B10-cancers-10-00214]\]. The most common chromosomal abnormalities at diagnosis of PV are trisomies of chromosomes 1, 8, and 9, as well as del(20q). Their role in the pathogenesis of the disease remains largely obscure and none of them are specific to PV. Although some reports have suggested that patients with PV carrying chromosomal aberrations at the time of diagnosis have a shorter survival and increased risk of AML/MDS compared to those with a normal karyotype \[[@B11-cancers-10-00214]\] the predictive prognostic value of chromosomal aberrations has not yet been established in PV.

A decade ago the first reports on oncogenic mutations in *JAK2* appeared \[[@B12-cancers-10-00214],[@B13-cancers-10-00214],[@B14-cancers-10-00214],[@B15-cancers-10-00214],[@B16-cancers-10-00214]\]. It has been found that more than 95% of the PV patients harbor the common *JAK2*V617F mutation although with varying allelic burden. The mutation is not specific to PV as it is also found in other MPN's although with lower frequency as well as in MDS/AML albeit more rarely. The *JAK2*V617F mutation is apparently not the disease-initiating event in humans, although the mutation in mice models has been found to induce a PV-like phenotype \[[@B17-cancers-10-00214]\]. Still, no genetic defect entirely specific to PV has been identified.

Here we utilized several fluorescent in situ hybridization (FISH) applications an oligonucleotide array-based Comparative Genomic Hybridization (aCGH) analysis in combination to characterize a *JAK2*V617F positive PV patient harboring the novel acquired t(2;4)(q36.1;q24) and a concurrent interstitial microdeletion at 4q23q24.

2. Results {#sec2-cancers-10-00214}
==========

2.1 Clinical Description {#sec2dot1-cancers-10-00214}
------------------------

A 64-year-old female presented with a weight loss of 2-3 kg over a period of 3 months, pruitus and intermittent night sweat. Biochemical analysis revealed a hemoglobin concentration of 13.2 mmol/L (reference interval (RI) females: 7.3--9.5) and hematocrit \>0.60 (RI females: 0.35--0.46). The platelet count was 372 × 10^9^/L (RI: 165--400 × 10^9^/L), and the leucocyte count was 10.9 × 10^9^/L (RI: 3.5--10.0 × 10^9^/L). The reticulocyte count was increased at 145 × 10^9^/L (RI: 31--97 × 10^9^/L). The plasma erythropoietin was suppressed at \<1.0 IU/L (RI: 5--30 IU/L). A bone marrow biopsy displayed features characteristic of PV with trilineage hyperplasia. The spleen was not enlarged upon clinical examination. The patient had a *JAK2*V617F mutation with an allelic burden of 71% and FISH excluded *BCR-ABL1* fusion gene. The patient was treated with phlebotomy, acetylsalicylic acid and required cytoreductive therapy with hydroxyurea or pegylated interferon alfa-2a due to intermittent thrombocytosis and leucocytosis during disease course ([Supplementary Figure S1](#app1-cancers-10-00214){ref-type="app"}). The total follow-up time was 64 months and she is now in continuous treatment with phlebotomy, hydroxyurea and acetylsalicylic acid.

2.2 Cytogenetic Analyses {#sec2dot2-cancers-10-00214}
------------------------

The karyotype, examined by G-banding analysis combined with 24-color karyotyping and mBanding analysis with chromosome 2 probes, was pseudodiploid harboring an apparently balanced reciprocal translocation between chromosomes 2 and 4 described as 46,XX,t(2;4)(q35;q21)\[18\]/46,XX\[7\] ([Figure 1](#cancers-10-00214-f001){ref-type="fig"}). To establish whether this translocation was constitutional or belonged to the malignant clone a peripheral blood sample was requested. G-banding after phytohaemagglutinin (PHA)-stimulated culturing showed a normal female karyotype 46,XX\[25\] (data not shown) indicating that the aberrant t(2;4) belongs to the malignant clone.

2.3 Oligo-Based Array Comparative Genomic Hybridization (CGH) Analysis {#sec2dot3-cancers-10-00214}
----------------------------------------------------------------------

High-resolution oligo-based aCGH (oaCGH) analysis revealed an approximately 5.4 Mb large deletion at chromosome 4 band region q23 to q24 ([Figure 2](#cancers-10-00214-f002){ref-type="fig"}A,B). The minimal region of deletion encompassed the following probes A_16_P36844152 to A_16_P36856072, mapping from 101,572,440 bp to 106,955,633 bp and the maximal region of deletion encompassed probes A_16_P368440787 to A_16_P16801426 mapping from 101,550,452 bp to 106,975,209 bp. The deleted region affected 40 RefSeq genes including *TET2* and *CXXC4* ([Table 1](#cancers-10-00214-t001){ref-type="table"}). It is to be noted that the aCGH analysis did not disclose any further copy number alterations, neither on chromosome 2.

2.4 Validation by FISH Analyses {#sec2dot4-cancers-10-00214}
-------------------------------

To validate the above aCGH findings we performed FISH analysis using the bacterial artificial chromosomes (BAC)-based probes RP11-842N10 and RP11-867L22 together with centromeric probe D4Z1 ([Figure 2](#cancers-10-00214-f002){ref-type="fig"}C,D). This analysis confirmed the mono-allelic nature of the deletion in both metaphases and interphase nuclei and that the deletion involved the same chromosome 4 derivative being involved in the t(2;4). After counting of 200 nuclei we found that 150 nuclei exhibited a 2G1R2A pattern, indicating that 75% of the cells carried the deletion in the diagnostic sample. Fluorescence In Situ Hybridization on PHA-stimulated cultured white blood cells from peripheral blood with the probes RP11-842N10, RP11-867L22, and D4Z1 exhibited a normal signal pattern 2G2R2A in 100% of interphase nuclei and on metaphases demonstrating that the observed abnormalities are acquired and belong to the abnormal hematopoietic cells.

2.5 Breakpoint Mapping by FISH Analyses {#sec2dot5-cancers-10-00214}
---------------------------------------

To establish the breakpoint region on chromosomes 2 and 4 more precisely we used a panel of BAC-based probes in different combinations ([Table 2](#cancers-10-00214-t002){ref-type="table"} and [Figure 3](#cancers-10-00214-f003){ref-type="fig"}). From these FISH analyses we were able to determine that the breakpoint region on chromosome 2 is located within the BAC-probe RP11-79C2 and on chromosome 4 within the BAC-probe RP11-13F20.

Taken together, we have shown that an approximately 5.4 Mb large chromosomal segment encompassing the bands 4q23q24 is deleted and that this event is accompanied by a reciprocal translocation of the telomeric 4q24-qter segment with the 2q36.1-qter segment as summarized in [Figure 4](#cancers-10-00214-f004){ref-type="fig"}A. The final karyotype resulting from conventional cytogenetics, FISH and aCGH investigations, according to ISCN 2013, of bone marrow at diagnosis is: 46,XX,der(2)t(2;4)(q36.1;q24),der(4)del(4)(q23q24)t(2;4)(q36.1;q23)\[18\]/46,XX\[7\].nuc ish(RP11-842N10x1,RP11-867L22x2,D4Z1x2)\[150/200\].arr\[hg18\] 4q23q24(101,561,446-106,965,421)x1.

In silico analysis of the involved regions suggested that the 5′-part of *EMCN* gene (spanning exons 1 to 5) at 4q23 and the 5′-part of *GSTCD* gene (spanning exons 1 to 5) at 4q24 were deleted ([Figure 4](#cancers-10-00214-f004){ref-type="fig"}B). The fusion of the chromosomal regions 4q23 and 2q36.1 on der(4)t(2;4) could theoretically form the fusion gene *SERPINE*-*EMCN*. The fusion on der(2)t(2;4) involved the 5′-part of the *GSTCD* gene on 4q24, but it could not be determined which of the *WDFY1*, *MRPL4* or *SERPINE* genes on 2q36.1 that might be involved in the translocation event due to lack of genomic resolution. Unfortunately, we could not perform gene expression or RNA sequencing analyses to establish possible presence of a fusion gene or altered expression of involved genes due to lack of additional sample material.

3. Discussion {#sec3-cancers-10-00214}
=============

Polycythemia vera has an inherent tendency to transform into myelofibrosis (MF), MDS or AML \[[@B18-cancers-10-00214]\]. The cumulative incidence of post-PV MF evolution is 5--14% at 15 years \[[@B19-cancers-10-00214],[@B20-cancers-10-00214],[@B21-cancers-10-00214]\] and for post-PV MDS/AML the estimated transformation rates are 2.3% at 10 years and remains \<10% at 20 years \[[@B22-cancers-10-00214],[@B23-cancers-10-00214]\]. The survival rates of PV shorten after transformation to either MF or MDS/AML. Factors influencing these survival rates include: age, leukocytosis, abnormal karyotype, splenomegaly, bone marrow reticulin grade, and *JAK2*V617F mutant allele burden \[[@B19-cancers-10-00214],[@B23-cancers-10-00214],[@B24-cancers-10-00214],[@B25-cancers-10-00214],[@B26-cancers-10-00214],[@B27-cancers-10-00214],[@B28-cancers-10-00214]\]. It is evident that the process of transformation in PV is complex and at present it is not possible to accurately predict which PV patients that will transform or not.

Cytogenetic abnormalities may play a role in the transformation process as the frequency of chromosomal aberrations in PV is approximately 20% at diagnosis but much higher among patients transforming to AML \[[@B7-cancers-10-00214],[@B8-cancers-10-00214],[@B9-cancers-10-00214],[@B10-cancers-10-00214]\]. Trisomy 8 and 9, and abnormalities of chromosome 1, 20q-, 13q-, 11q-, 3p-, and dup13 have most frequently been observed, especially in older patients \>60 years of age \[[@B4-cancers-10-00214],[@B7-cancers-10-00214]\]. A minority of PV patients have been shown to have acquired various translocations at diagnosis including t(2;11)(p21;q23) \[[@B29-cancers-10-00214]\], t(16;20)(q22;p13) \[[@B30-cancers-10-00214]\], and der(18)t(9;18)(p13;p11) or der(9;18)(p10;q10) \[[@B31-cancers-10-00214]\]. However, the role of these different types of cytogenetic abnormalities in transformation of PV remains obscure, and cytogenetic abnormalities have not been shown to carry prognostic relevance \[[@B5-cancers-10-00214]\].

In this study, we found a t(2;4)(q36.1;q24) in a female with *JAK2*V617F-positive PV at diagnosis with a follow-up period of 5 years where her disease has not transformed to MF or MDS/AML. The identified t(2;4) translocation is to the best of our knowledge novel as searches in Mitelman \[[@B32-cancers-10-00214]\] and literature databases revealed no additional cases. In addition, a search in our local registry with more than 20,000 entries of different hematological malignancies since 2001 was also without additional cases. By aCGH analysis we detected an additional concurrent submicroscopic 5.4 Mb large deletion at 4q23q24, and it was confirmed by FISH analyses that the deletion was located on the der(4)t(2;4) at the 4q24 translocation breakpoint. Both of these chromosomal abnormalities were acquired because cytogenetic analyses of surrogate germ-line cells were without the detected aberrations.

Chromosomal aberrations involving chromosome band 2q36 have been reported in 15 MDS or AML cases \[[@B32-cancers-10-00214]\]. The reported aberrations include: t(1;2)(q21-q22;q36) \[[@B33-cancers-10-00214],[@B34-cancers-10-00214],[@B35-cancers-10-00214]\], t(X;2)(p22;q36) \[[@B36-cancers-10-00214]\], t(2;17)(q36;q11) \[[@B37-cancers-10-00214],[@B38-cancers-10-00214]\], and del(2)(q23-q35q36) \[[@B39-cancers-10-00214],[@B40-cancers-10-00214],[@B41-cancers-10-00214]\]. In the present PV patient, we performed chromosome walking utilizing several different FISH probes and mapped the translocations breakpoint to be within the BAC-clone RP11-79C2 at 2q36.1 (genomic pos. 224,460,665--224,627,199; hg18). There are three genes located within this BAC-clone: *WDFY1*, *MRPL44* and *SERPINE2*. In silico analysis revealed that *SERPINE2* theoretically could form a fusion gene with the *EMCN* at 4q23 ([Figure 4](#cancers-10-00214-f004){ref-type="fig"}). The *SERPINE2* gene, expressing a serine proteinase inhibitor clade E member 2, was recently shown to be a potential biomarker for tumor diagnosis and prognosis in a variety of solid tumors \[[@B42-cancers-10-00214]\]. Although the *EMCN* gene previously has been shown to be overexpressed in acute leukemia \[[@B43-cancers-10-00214]\] further studies are needed to clarify the potential role, if any, of the *SERPINE2* and *EMCN* genes in the pathogenesis of the present patient.

Chromosome band 4q24 is a more common chromosomal breakpoint region in myeloid malignancies as 34 cases have been reported in MDS or AML \[[@B32-cancers-10-00214]\]. The most frequent aberrations include: t(1;4)(p32;q24) \[[@B44-cancers-10-00214]\], t(1;4)(p35;q24) \[[@B45-cancers-10-00214]\], t(4;12)(q24;q12-q22) \[[@B46-cancers-10-00214],[@B47-cancers-10-00214],[@B48-cancers-10-00214]\], t(4;17)(q24;q25) \[[@B47-cancers-10-00214],[@B48-cancers-10-00214]\], t(X;4)(q22;q24) \[[@B49-cancers-10-00214]\], and del(4)(q21-q28) \[[@B50-cancers-10-00214],[@B51-cancers-10-00214],[@B52-cancers-10-00214],[@B53-cancers-10-00214],[@B54-cancers-10-00214],[@B55-cancers-10-00214],[@B56-cancers-10-00214]\]. In a study of four female AML or MDS patients the 4q24 band was involved in three apparently balanced translocations between 4q and a variable partner chromosome, including t(3;4)(q26;q24), t(4;5)(q24;p16), and t(4;7)(q24;q21), and one patient with a localized del(4)(q24q25) \[[@B57-cancers-10-00214]\]. Unexpectedly, the authors detected a concurrent submicroscopic deletion at 4q24 (localized between genomic positions 105,800,776 to 106,847,377; hg18) in all three patients harboring the apparently balanced translocations by metaphase FISH analyses using near-contiguous BAC-based probes. Interestingly, in our present patient we also detected a concurrent submicroscopic deletion, del(4)(q23q24), in addition to the t(2;4)(q36.1;q24). Taken together, it seems that the 4q24 chromosomal region may be directly or indirectly associated with pathogenesis in a subset of hematological disorders.

In our patient aCGH analysis defined the concurrent deletion to be 5.4 Mb large encompassing 40 RefSeq genes, including *TET2* and *CXXC4*. *TET2* belongs to a group of ten-eleven-translocation (TET) proteins, Fe(II)- and α-ketoglutarate-dependent oxygenases, that modify 5-methylcytosine (5-mC) to e.g., 5-hydroxymethylcytosine (5-hmC) \[[@B58-cancers-10-00214],[@B59-cancers-10-00214]\], which seems to be an important step in the active demethylation of DNA \[[@B60-cancers-10-00214]\]. Loss of *TET2* function is associated with a continuous enlargement of the hematopoietic stem cell compartment leading to myeloproliferation by a mechanism of increased hematopoietic stem cell self-renewal and myeloid transformation as indicated by studies in mice \[[@B61-cancers-10-00214],[@B62-cancers-10-00214]\]. *TET2* mutations have been described in a wide range of myeloid malignancies with a mutation frequency of 7 to 13% \[[@B63-cancers-10-00214],[@B64-cancers-10-00214]\]. These mutations are typically small deletions, insertions, or nonsense mutations that are expected to induce loss-of-function in the protein. The catalytic activity of TET2 might be impaired by missense mutations affecting conserved amino acids in TET2, which can result in lower global 5-hmC levels in TET2-mutated patients compared with wild-type TET2 \[[@B65-cancers-10-00214]\].

The *CXXC4* gene is a negative regulator of Wnt signaling pathway and also regulates the *TET2* expression, where co-expression of *CXXC4* and *TET2* resulted in a decrease in levels of 5-hmC \[[@B66-cancers-10-00214]\]. The homeostatic self-renewal of stem cells in adult tissues is regulated by the Wnt signaling pathway \[[@B67-cancers-10-00214]\], and its constitutive activation contributes to cancer development and progression \[[@B68-cancers-10-00214],[@B69-cancers-10-00214],[@B70-cancers-10-00214]\]. Other genes involved in regulation of Wnt pathways include the *ASXL1, ASXL2, UTX, CXXC4, CXXC5, TET2*, and *TET3* genes as indicated by MDS patients harboring mutations in these genes \[[@B71-cancers-10-00214]\]. The *CXXC4* gene has been associated with development of renal carcinoma \[[@B72-cancers-10-00214]\], colonic villous adenoma \[[@B73-cancers-10-00214]\], and gastric cancer \[[@B74-cancers-10-00214]\].

Our study patient had, in addition to the t(2;4) and del(4)(q24q24), a high allelic burden of *JAK2*V617F mutation (equivalent to 71%) which was similar the number of cells harboring the 4q24 deletion. This finding is in line with observations that the most common co-occurring classes of mutations in MPNs are signaling mutations (e.g., *JAK2*V617F) and mutations in genes involved in epigenetic regulation (e.g., *TET2*) \[[@B75-cancers-10-00214]\]. Progression in PV patients may result from co-occurring mutations in *JAK2*V617V and *TET2* because loss of *TET2* might drive clonal dominance in hematopoietic stem cells and that *JAK2*V617V expression might cause expansion of precursor cell populations \[[@B75-cancers-10-00214]\]. Furthermore, it was observed that treatment of PV patients carrying both *TET2* and *JAK2* mutations experienced reduction in the *JAK2* mutant clones without significant eradication of the *TET2* mutant clone \[[@B76-cancers-10-00214]\]. This was also observed in PV patients during PEG-IFN-α-2a therapy where the *TET2* mutant clones persist despite eradication of *JAK2*V617F clones \[[@B75-cancers-10-00214]\]. In some patients pegylated interferon alfa-2a has the ability to induce complete bone marrow responses \[[@B77-cancers-10-00214]\]. Our patient was initially treated with phlebotomy, cytoreductive (hydroxyurea) and anti-thrombotic therapy but due to persistent pruritus and high platelet counts cytoreductive treatment was changed to pegylated interferon alfa-2a for a period of approximately 14 months ([Supplemental Figure S1](#app1-cancers-10-00214){ref-type="app"}). Unfortunately, we do not have any molecular follow-up data on allelic burden of *JAK2*- or *TET2*-mutations to document potential changes in mutation burdens of these mutations but she responded clinical well. Another limitation of this study is that the follow-up of the present patient is relatively short, a little more than 5 years, as it is known that PV may transform after up to 20 years.

Only a few studies have used aCGH or single nucleotide polymorphism (SNP) analysis in characterizing PV genomic aberrations. In a study of 26 PV patients high density oligo-based aCGH analysis detected copy number alterations in 35% of the patients at diagnosis \[[@B78-cancers-10-00214]\]. Another study of 14 PV patients concluded that microdeletions and microduplications do not have an essential role in the development of PV as detected by high-density oligo-based aCGH analysis \[[@B79-cancers-10-00214]\]. A study using high-resolution SNP microarrays revealed a common uniparental disomy (UPD) of chromosome 9p or gain of 9p in addition to other copy number aberrations in a small cohort of post-PV MF patients with elevated *JAK2*V617F mutation burden \[[@B80-cancers-10-00214]\]. Our present study together with these previous studies underscores the value of using aCGH or SNP analysis in characterizing genomic alterations in PV at least in subsets of patients with e.g., translocations involving chromosome band 4q24.4.

4. Materials and Methods {#sec4-cancers-10-00214}
========================

4.1 Cytogenetic Analysis {#sec4dot1-cancers-10-00214}
------------------------

Unstimulated overnight cultures of bone marrow sample from the patient were examined according to our standard laboratory protocols. Phytohemagglutinin (PHA)-stimulated culture from a peripheral blood sample was established at a later time point to examine whether identified chromosomal abnormalities were acquired or congenital. Chromosome preparations were treated and stained by Giemsa-banding. Karyotypes were described according to *An International System for Human Cytogenetic Nomenclature* (ISCN, 2013) \[[@B81-cancers-10-00214]\]. Written informed consent was obtained from the patient.

4.2 FISH Analysis {#sec4dot2-cancers-10-00214}
-----------------

To characterize the chromosome rearrangement multicolor FISH were done on chromosome preparations from bone marrow according to manufacturer's instructions using the following human XCyting multicolor FISH probes (MetaSystems, Altlussheim, Germany): (1) 24-color karyotyping was done with the 24XCyte kit consisting of 24 different chromosome painting probes; and (2) mBanding with XCyting probes for chromosome 2 consisting of a series of partial chromosome paint probes for sequential partially overlapping chromosome regions of a single chromosome. Each of the XCyte probes was labeled with one of five fluorochromes or a unique combination thereof (combinatorial labeling). Metaphases were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Image capture was done with an automated Zeiss Axio Imager.Z2 equipped with a couple-charged device (CCD)-camera (CoolCube1, MetaSystems, Altlussheim, Germany) and appropriate filters (MetaSystems, Altlussheim, Germany). Karyotyping was done using the 24-color mFISH upgrade package, ISIS, including mBanding.

Locus-specific directly fluorescent-labeled BAC probes (Empire Genomics, Buffalo, NY, USA) on chromosomes 2 and 4 were used for validation of identified microdeletion by oaCGH analysis and break point mapping together with SE4 (D4Z1) (Kreatech, Amsterdam, The Netherlands). To estimate the number of abnormal cells 200 interphase nuclei was evaluated by two independent observers. All locus-specific analyses were done according to manufacturer's instructions. To identify the common dual fusion probe *BCR-ABL1* (Abbott Molecular, Wiesbaden, Germany).

4.3 oaCGH Analysis {#sec4dot3-cancers-10-00214}
------------------

The CytoChip Cancer 4 × 180 K v2.0 (BlueGnome, Cambridge, UK) encompassing a 20 kb backbone with highest concentration of probes at 670 cancer genes was used for oaCGH analysis according to manufacturer's instructions as described in \[[@B82-cancers-10-00214]\]. DNA purified from bone marrow cells was used together with pooled female genomic DNA as reference. After hybridization, washing and drying, the oligo array was scanned at 2.5 µm with GenePix 4400A microarray scanner. Initial analysis and normalization was done with BlueFuseMulti v2.6. For analysis and visualization normalized log2 probe signal values were imported into Nexus Copy Number software v. 6.1 (BioDiscovery, CA, USA) and segmented using FASST2 segmentation algorithm with a minimum of 3 probes/segment. Regions of gain or loss contained within copy number variable regions (CNVs) were discarded. Reference genome was NCBI build 36.1 (hg18). The UCSC database (<http://genome.ucsc.edu>) was used for bioinformatics analysis.

4.4 JAK2 Mutation Analysis {#sec4dot4-cancers-10-00214}
--------------------------

DNA extracted from peripheral blood leukocytes after red blood cell lysis was used for *JAK2*V617F mutation analysis, which was done by allele-specific polymerase chain reaction as described \[[@B12-cancers-10-00214]\].

5. Conclusions {#sec5-cancers-10-00214}
==============

In summary, we identified a novel apparently balanced t(2;4)(q36.1;q24) with a concurrent cryptic del(4)(q23q24) in a *JAK2*V617F positive PV patient. The submicroscopic deletion was detected by aCGH analysis and found to be 5.4 Mb in size encompassing 40 RefSeq genes, including *TET2* and *CXXC4*. FISH analysis confirmed that the interstitial submicroscopic mono-allelic deletion at 4q was on der(4)t(2;4).

Our findings agree with observations from mice model systems where concomitant *JAK2*V617F expression and *TET2* loss promote accelerated myeloproliferation but no overt fibrotic or leukemic transformation. It is, therefore, important to identify PV patients that are positive for both *TET2*- and *JAK2*-mutations to offer optimal treatment options. To identify this group of *JAK2*V617F positive PV patients harboring concomitant *TET2* loss we suggest including either locus-specific FISH analysis covering the *TET2* locus or oaCGH analysis to detect copy number changes in chromosome band 4q24.

The observed del(4)(q23q24) in our patient also encompassed the *CXXC4* gene which is a known regulator of *TET2* expression, but the impact of this observation must await further studies.

The present findings provide additional clues to unravel important molecular pathways in PV to obtain the full spectrum of acquired chromosomal and genomic aberrations. As more cases become characterized at the molecular level this may eventually improve on treatment options.
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The following are available online at <http://www.mdpi.com/2072-6694/10/7/214/s1>, Figure S1: Longitudinal biochemical analyses and treatment overview.
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![Multi-color Fluorescence in Situ Hybridization (FISH). (**A**) 24-color karyotyping revealed the translocation t(2;4). White arrows indicate the derivative chromosomes. (**B**) mBanding analysis of chromosomes 2. The single-color gallery tool in ISIS software shows assigned false colors (FC) and individual color schemes of labeled chromosomes arranged in their capture sequence FITC (fluorescein isothiocyanate), SpO (spectrum orange), TR (Texas red), Cy5 (cyanine), DEAC (7-diethylaminocoumarin-3-carboxylic acid, succinimidyl ester). Upper row shows the normal chromosome 2, middle row shows the der(2)t(2;4) and lower row show the der(4)t(2;4) from the patient's karyotype. The right-hand side shows a schematic representation of the localization of the different multicolor probes of XCyte 2 relative to the ideogram of chromosome 2 together with breakpoint marked by the arrow.](cancers-10-00214-g001){#cancers-10-00214-f001}

![Oligo-based array Comparative Genomic Hybridization (oaCGH) analysis and FISH validation. (**A**) Whole genome view of the bone marrow sample showing a submicroscopic deletion at chromosome 4 indicated by the arrow. Horizontal blue lines indicate log~2~ ratios +0.24 and +0.60 and red lines indicate log~2~ ratios −0.24 and −1.0. The X-axis at the bottom indicates chromosomal position. (**B**) Chromosome view of chromosome 4 with deletion at 4q23-q24 indicated by an arrow and ideogram of chromosome 4 to the left. (**C**) A zoom view of the deleted region as indicated by red shade corresponding to the deletion's maximal chromosomal position. The red and green bars indicate the position of FISH probes used for validation. (**D**) FISH using BAC (Bacterial Artificial Chromosomes) probes RP11-842N10 (red) and RP11-867L22 (green) at 4q23 and 4q24, respectively, and centromeric probe D4Z1 (aqua) confirms the interstitial mono-allelic deletion and translocation in nuclei and metaphases from the patient.](cancers-10-00214-g002){#cancers-10-00214-f002}

![Break point mapping with FISH probes. Partial karyograms of normal chromosome 2, der(2)t(2;4), normal chromosome 4, and der(4)t(2;4) arranged from top to bottom showing FISH results after hybridization using respective dual color probe sets as indicated at the top. WCP indicates whole chromosome painting, and chromosome 4 is indicated by the centromeric D4Z1 probe (aqua).](cancers-10-00214-g003){#cancers-10-00214-f003}

![Model of chromosomal rearrangement. (**A**) Schematic representation of the translocation between chromosomes 2 and 4 with breakage points indicated by arrows together with the deleted region followed by reciprocal joining. (**B**) Schematic representation of genes (light brown boxes) mapping in correspondence to the breakpoint regions. Upper panel shows the joined regions of 2q36.1 and 4q24 and the lower panel shows the joined regions 4q23 and 2q36.1. The deleted chromosomal fragment del(4)(q23q24) is omitted and the genes located in this region are listed in [Table 2](#cancers-10-00214-t002){ref-type="table"}. The axis at the bottom of each panel indicates the chromosomal position of the involved regions. The resolution of the aCGH analysis is limited to the kilobase pair level and the density of the oligo probes differ according to chromosomal regions with the highest density at known cancer genes. Vertical red and green bars indicate the relative genomic position of deleted (red) and not deleted (green) oligonucleotide probes in the aCGH analysis. Vertical yellow bars indicate the position of BAC clone RP11-79C2 being involved in the translocation.](cancers-10-00214-g004){#cancers-10-00214-f004}
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###### 

Genes located in the deleted region on chromosome 4.

  Gene Symbol             Chromosome   Start         End           Length (bp)
  ----------------------- ------------ ------------- ------------- -------------
  EMCN                    chr4         101,535,520   101,658,273   122,754
  LINC01216               chr4         101,800,458   101,815,293   14,836
  DKFZp761L0516           chr4         102,163,609   102,487,057   323,449
  PPP3CA                  chr4         102,163,609   102,487,651   324,043
  MIR8066                 chr4         102,380,974   102,381,052   79
  FLJ20021                chr4         102,487,956   102,489,063   1108
  AK000028                chr4         102,487,959   102,489,062   1104
  BANK1                   chr4         102,560,140   103,214,992   654,853
  SLC39A8                 chr4         103,391,220   103,485,678   94,459
  NFKB1                   chr4         103,641,517   103,757,507   115,991
  MANBA                   chr4         103,771,690   103,901,196   129,507
  LOC102723704            chr4         103,917,265   103,939,844   22,580
  CR618043                chr4         103,934,626   103,936,350   1725
  UBE2D3                  chr4         103,934,619   104,009,491   74,873
  AK093356                chr4         103,968,428   103,984,352   15,925
  CISD2                   chr4         104,009,575   104,033,412   23,838
  NHEDC1                  chr4         104,025,643   104,160,325   134,683
  SLC9B1                  chr4         104,025,641   104,160,345   134,705
  NHEDC2                  chr4         104,160,837   104,217,379   56,543
  SLC9B2                  chr4         104,166,096   104,217,977   51,882
  BDH2                    chr4         104,218,230   104,240,473   22,244
  UNQ6308                 chr4         104,218,230   104,240,473   22,244
  CENPE variant protein   chr4         104,278,956   104,281,020   2065
  CENPE                   chr4         104,246,411   104,339,015   92,605
  LOC101929448            chr4         104,565,647   104,580,334   14,688
  TACR3                   chr4         104,730,073   104,860,422   130,350
  AK093871                chr4         105,609,014   105,612,315   3302
  CXXC4                   chr4         105,608,911   105,635,507   26,597
  AK094561                chr4         105,631,570   105,816,794   185,225
  LOC101929468            chr4         105,631,570   105,838,198   206,629
  TET2                    chr4         106,286,480   106,420,409   133,930
  PPA2                    chr4         106,509,682   106,614,676   104,995
  BC008246                chr4         106,612,473   106,614,625   2153
  EEF1AL7                 chr4         106,625,311   106,626,956   1646
  ARHGEF38-IT1            chr4         106,702,196   106,710,841   8646
  FLJ20184                chr4         106,693,225   106,772,286   79,062
  ARHGEF38                chr4         106,693,225   106,821,519   128,295
  AK125951                chr4         106,799,802   106,821,519   21,718
  INTS12                  chr4         106,823,233   106,849,330   26,098
  GSTCD                   chr4         106,849,389   106,988,331   138,943

Bp: base pairs.

cancers-10-00214-t002_Table 2

###### 

BAC-based FISH probes used to characterize the break points of the t(2;4)(q22;q24).

  Cytoband   Position \[hg18\]          Probe          Result on Derivative Chromosomes
  ---------- -------------------------- -------------- ----------------------------------------------------------------------------------------------------------------------------------
  4q23       101,510,593--101,671,984   RP11-13F20     Partially deleted on der(4), and fused with RP11-79C2
  4q23       101,560,500--101,762,033   RP11-842N10    Deleted on der(4)
  4q24       107,113,145--107,319,249   RP11-867L22    On der(2)
  4p10q10                               D4Z1           On der(4)
  2q35       218,520,847--218,639,368   RP11-129D2     On der(2)
  2q36.1     221,626,882--221,799,537   RP11-451C18    On der(2)
  2q36.1     224,095,528--224,291,965   RP11-726G4     On der(2)
  2q36.1     224,301,090--224,460,665   RP11-183N7     On der(2)
  2q36.1     224,460,665--224,627,199   RP11-79C2      The probe is unevenly split between der(2) and der(4) by 75% and 25% signal intensity, respectively. It is fused with RP11-13F20
  2q36.1     224,625,674--224,809,242   RP11-8F7       On der(4)
  2q36.2     225,077,009--225,253,855   RP11-110D2     On der(4)
  2q36.2     225,527,112--225,706,569   RP11-1047B17   On der(4)
  2q36.3     226,764,027--226,939,580   RP11-59L19     On der(4)
  2q36.3     228,283,721--228,440,226   RP11-90L9      On der(4)
